BioScale Launches New Acoustic Assay 6-Plate Format Cartridge for Use on ViBE? Platform to Further Increase Productivity and Cost-Efficiency of Protein Analyses - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
BioScale Launches New Acoustic Assay 6-Plate Format Cartridge for Use on ViBE? Platform to Further Increase Productivity and Cost-Efficiency of Protein Analyses


BioScale Launches New Acoustic Assay 6-Plate Format Cartridge for Use on ViBE™ Platform to Further Increase Productivity and Cost-Efficiency of Protein Analyses

PR Newswire

LEXINGTON, Mass., May 21, 2014 /PRNewswire/ -- BioScale, Inc., a leading supplier of novel protein measurement technology to accelerate the development of biological and pharmaceutical products, today announced the launch of a new, 6-plate cartridge format for its Acoustic Assays to enable larger protein analysis studies, with unprecedented cost efficiency. The product enhancement, for use on the company's proprietary ViBE instrumentation platform, was introduced at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego.

"Our ViBE platform, paired with our non-optical Acoustic Assays, overcomes limitations of traditional methods like ELISA or Western blot by providing a simple, highly sensitive method of measuring specific proteins in a complex sample, with walk-away automation. This enables fast assay development – that takes days, rather than months," said Christopher Silva, Vice President, Commercial Operations at BioScale. "Now, our new 6-plate format enables even larger studies – providing up to 576 data points in one cartridge – at a cost as low as only $2 per sample well. This will be particularly important for scientists needing to study cell signaling pathways and biomarkers, who are running larger cohorts in the areas of oncology, CNS, cardiovascular and inflammation research – areas where the platform is currently utilized."

BioScale's ViBE platform enables non-optical, acoustic protein measurement utilizing BioScale's proprietary AMMP™ (Acoustic Membrane MicroParticle) technology. The company's Acoustic Assays measure analyte concentration by determining changes in oscillation frequency caused by the binding of microparticles to the sensor surface. To date, the platform featured 1-, 2- and 3-plate cartridge formats allowing up to 288 samples per cartridge. Now, the 6-plate format allows up to 576 individual data points in a single assay or the re-use of the cartridge for multiple assays for up to 576 measurements across 5 days.

"BioScale's new 6-plate cartridge allows us to run more than 500 samples in a week, with a simple pipette-and-go workflow, dramatically increasing the accuracy of our study results," said Cloud Paweletz, Ph.D., of the Belfer Institute for Applied Cancer Science at the Dana Farber Cancer Institute, who beta tested the new product.

About BioScale, Inc.
BioScale manufactures and markets the ViBE™ platform, a novel protein measurement technology enabling highly sensitive, automated Acoustic Immunoassays™ to accelerate drug discovery, development and production of biological and pharmaceutical products. The sensitivity, precision and walk-away capabilities of our non-optical AMMP technology enables customers to achieve breakthrough advancements in protein research that were not previously attainable via tradition ELISA, Western blot and IHC methods, allowing ultra-sensitive detection of proteins in complex biological samples. The company's instrumentation platform is used by leading biopharmaceutical companies, academic institutions and government laboratories. BioScale is headquartered in Lexington, Mass.

Media Contact:
Lisa Rozamus
781.430.6800
lrozamus@bioscale.com

SOURCE BioScale, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here